LYNPARZA breast cancer in the adjuvant setting Japan Post-Marketing Surveillance (PMS)

Study identifier:D081CC00012

ClinicalTrials.gov identifier:NCT05677308

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

LYNPARZA Tablets 100mg, 150mg general drug use-results study in patients with BRCA mutated HER2 negative high recurrent risk breast cancer in the adjuvant setting

Medical condition

Breast Cancer

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

104

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 07 Mar 2023
Estimated Primary Completion Date: 31 Dec 2026
Estimated Study Completion Date: 31 Dec 2026

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria